Prime Medicine doses first patient in Wilson disease gene editing trial

October 5, 2026 8:00 AM

Prime Medicine, Inc. (Nasdaq: PRME) announced that the first patient has been dosed in its global Phase 1/2 clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found